Study compares human vitrification kits for equine embryos: full analysis

A new Equine Veterinary Journal study points to a simple but potentially meaningful variable in equine embryo cryopreservation: the commercial vitrification kit itself. Sandra Wilsher and colleagues compared three human embryo vitrification kits for use with in vivo produced equine embryos and found similar pregnancy rates in smaller embryos, but better results with the Kitazato kit in embryos measuring 400-500 μm. The paper was published in 2025 as DOI 10.1111/evj.14539. (colab.ws)

That finding lands in a part of equine reproduction where progress has been steady, but not simple. Equine embryos have long posed a cryopreservation challenge because they expand rapidly after entering the uterus, and larger embryos tolerate freezing poorly. Reviews and background materials have noted that smaller embryos generally survive vitrification well, while larger embryos often require more tailored handling. Wilsher’s prior work has been central to that shift, including studies on puncture or blastocoele collapse for larger embryos, and more recent evidence that some embryos above 300 μm can be vitrified successfully without puncture when protocols are optimized. (sciencedirect.com)

In the new comparison, the variable of interest was the kit formulation, especially the non-penetrating cryoprotectant system. A secondary source summarizing the paper reports that 108 embryos were assigned across Kitazato, Vit Kit Freeze, and Vit Kit Freeze NX. Kitazato used trehalose plus hydroxypropyl cellulose, while Vit Kit Freeze used sucrose plus Dextran Serum Supplement, and Vit Kit Freeze NX used trehalose plus Dextran Serum Supplement. Manufacturer documentation supports those formulation differences: Kitazato describes trehalose and hydroxypropyl cellulose as notable components, while FUJIFILM Irvine Scientific’s Vit Kit Freeze NX lists trehalose and dextran serum supplement in its vitrification media. (madbarn.com)

That composition detail matters because the study’s signal appears tied to embryo size. The abstract summary indicates equivalent pregnancy rates for smaller embryos, but superior outcomes with Kitazato for embryos in the 400-500 μm bracket. Mechanistically, that’s plausible rather than surprising: as embryo size increases, the margin for error in dehydration, osmotic stress, and warming injury narrows. Earlier equine and broader embryo cryobiology literature has already suggested that disaccharides and macromolecules can affect post-warming viability, and prior equine work has shown that outcomes can change sharply once embryos move beyond the more forgiving small-embryo range. (madbarn.com)

I didn’t find a separate press release or broad industry reaction tied specifically to this paper. But the result is consistent with the direction of recent commentary from Wilsher and colleagues, who have argued that equine embryo cryopreservation is becoming more clinically usable when practitioners match technique to embryo size. In related recent work, the same group reported pregnancy rates of 81.8% for embryos ≤300 μm and 80% for embryos >300-500 μm using a human vitrification kit with a longer equilibration exposure, while embryos >500 μm did not survive in that protocol. A newer PubMed-listed paper from the group also points to continued refinement of warming methods for vitrified in vivo equine embryos. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, especially theriogenologists and embryo transfer programs, this is the kind of data that can change a standard operating procedure. If smaller embryos perform similarly across kits, clinics may have flexibility there. But if outcomes diverge in the 400-500 μm range, kit selection becomes a real clinical decision for practices trying to expand cryopreservation options without sacrificing pregnancy rates. It also reinforces that “human IVF” products used in equine programs aren’t interchangeable just because their headline cryoprotectants look similar; the supporting excipients and macromolecules may influence performance in species-specific ways. (madbarn.com)

There’s also a workflow implication. A kit that improves survival in embryos nearing 500 μm could widen the practical collection window for donor mares and reduce the pressure to recover only very small embryos. That could make cryopreservation more usable in commercial programs where recipient synchronization, shipping, and scheduling still create friction. At the same time, the broader literature suggests clinics should be cautious about overextending the finding: once embryos get beyond about 500 μm, success remains much less predictable, even with newer protocols. (ivis.org)

What to watch: The next step is validation in larger commercial datasets, ideally with direct reporting of pregnancy, early loss, and foaling outcomes by embryo size band and kit, plus more clarity on whether the advantage comes from trehalose, hydroxypropyl cellulose, or the full protocol package. (madbarn.com)